

OA PARTNERS WITH MICROSYS TO PROVIDE PRACTICE MANAGEMENT SOFTWARE

Oncology Associates is excited to partner with MICROSYS, the providers of MicroMD, a comprehensive Practice Management System.



MicroMD instantly puts the information you need – schedules, lab results, medications, diagnoses, encounters – right at your fingertips. The system's automated workflow means no more printed schedules, change slips, or pink phone message slips. Tedious payment posting is handled automatically. Your billing is complete and accurate and your data is kept private and secure.

To find out more information about MicroMD, contact Tony DiPiero, MICROSYS Director of Sales at **800.624.8832, option four** and identify yourself as an OA Member. MICROSYS is supported by an established network of resellers across the United States who can customize to the individual needs of your practice. Visit OA's website at **www.oagpo.com** for more information on MicoMD.

Features of MicroMD:

- > Workflow Management
- > Task Management and Email
- > Wireless Charge Entry
- > Mail Merge and Collection System
- > Capitation Tracking
- > Multiple Insurance Plan Sets and Cases
- > HIPPA Privacy Alerts
- > Streamlined Insurance and Patient Billing
- > Online Appointments and Automatic Recall
- > Reporting Tools- Drill-down and Queues

Benefits to OA Members:

- > Improving A/R cycle due to split sequences in MicroMD, allowing for streamlined billing and quicker payments
- > Saving on outside printing costs
- > Saving on check-in time
- > Saving hours per week in printing route slips that used to be handwritten
- > Annual savings in label costs for outguides

AMENDMENT TO GSK AGREEMENT

ZOFRAN PREMIXED BAG



Effective October 1, 2005 Oncology Associates offers an additional performance rebate on Zofran Premixed Bag (NDC #00173-0461-00) based on quarterly purchasing volume.

Performance Rebate Qualifications: If your total market share for Zofran Injection and Oral is greater than or equal to 60%, the rebates below may be earned for each rebate period.

Volume Performance Rebate: If your actual purchase volume of Zofran Premix Bag (NDC #00173-0461-00) is equal to or greater than \$35,000 at contract price during the quarterly rebate period, a 3% performance rebate will be earned.

Zofran Injection	Performance Rebate	Zofran Injection & Oral Market Share within the 5HT3 Injectable Class
Bags	10%	≥ 60.00%
20 ml vial	12%	60.0-79.99%
20 ml vial	additional 6% (total 18%)	80.00-84.99%
20 ml vial	Additional 10% (total 28%)	≥ 85.00%

ARIXTRA INJECTION



In order for OA Members to qualify for a performance rebate on Arixtra Injection products (NDC# 007-3232-11, and NDC# 007-3236-11), you must meet the following criteria:

- > If your total market share for Arixtra with the Anti-Coagulant Injection class is greater than or equal to 5%, the following rebates may be earned for each rebate period.

Arixtra Injection	Performance Rebate	Arixtra Market Share within the Arixtra Anti-Coagulant Injection Class
Arixtra Injection	2%	5.00-9.99%
Arixtra Injection	Additional 5% (total 7%)	10.00-19.99%
Arixtra Injection	Additional 8% (total 15%)	≥ 20.00%